ZEPHYR注册研究30天结果:Zenith Alpha腹主动脉覆膜支架治疗AAA的疗效
ZEPHYR是一项多中心、非随机、单臂、核心实验室控制的前瞻性注册研究,纳入德国、比利时和荷兰14个中心的347例AAA患者,评估Zenith Alpha腹主动脉覆膜支架的30天技术及临床结果。30天治疗成功率为94.8%,技术成功率96.0%,临床成功率98.8%。
要点
- 30天治疗成功率为94.8%,技术成功率为96.0%。
- 30天临床成功率为98.8%,肢体闭塞率为0.9%。
- 30天内再干预率为1.7%。
核心结论
- 使用Zenith Alpha腹主动脉覆膜支架进行EVAR在短期内有效。
研究设计与样本
- 多中心、非随机、单臂、核心实验室控制的前瞻性注册研究,纳入14个中心的347例AAA患者。
- 纳入标准为非破裂AAA,最大直径≥50 mm或6个月内增大>5 mm,且AAA瘤颈长度≥10 mm(中心报告)。
- 主要结局指标为30天治疗成功,定义为技术成功和临床成功的复合终点。
主要发现
- 30天治疗成功率为94.8%(N=329)。
- 技术成功率为96.0%(N=333)。
- 30天临床成功率为98.8%(N=343)。
- 30天随访中3例(0.9%)发生肢体闭塞,1例(0.3%)发生Ib型内漏。
- 30天内再干预率为1.7%(N=6),再干预原因包括穿刺点假性动脉瘤1例、肢体并发症2例、支架相关的肾动脉闭塞2例和髂外动脉血栓形成1例。
临床怎么用
- Zenith Alpha腹主动脉覆膜支架可用于满足纳入标准的AAA患者的EVAR治疗,短期疗效良好。
局限性
- 长期结果尚未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To report technical and clinical 30-day results following treatment with the Zenith Alpha™ abdominal stent graft from the ZEnith alPHa for aneurYsm Repair Registry (ZEPHYR). METHODS: Multicenter, nonrandomized, single arm, core laboratory-controlled, prospective registry collecting data on the Zenith Alpha Abdominal Endovascular Graft being used in subjects with abdominal aortic aneurysms (AAA) from sites in Germany, Belgium, and The Netherlands between December 2016 and December 2019. Inclusion criteria were non-ruptured AAAs with a maximum diameter ≥50 mm or enlargement >5 mm over 6 months with an AAA neck length ≥10 mm (site reported). Primary outcome measure was treatment success at 30 days. Treatment success was defined as a combined endpoint consisting of technical and clinical success. Technical success was defined as successful stent graft delivery and deployment as well as successful removal of the delivery system. Clinical success at 30 days was defined as freedom from type I and III endoleak, aneurysm rupture, conversion to open surgery and stent graft occlusion. RESULTS: Three hundred forty-seven subjects were included from 14 sites with a median age of 73.0 years (IQR 68.0-79.0). Thirty-four patients were female (9.8%). The median AAA diameter was 58.3 mm (IQR 55.0-63.5). The median proximal neck diameter was 23.6 mm (IQR 22.0-25.2) with a median proximal neck length of 24.4 mm (IQR 15.0-34.8) and a median infrarenal neck angulation of 24.5° (IQR 15.0-35.0). The right and left common iliac diameter were 16.1 mm (IQR 14.1-19.4) and 16.2 mm (IQR 14.1-19.1), respectively. The treatment success rate at 30 days was 94.8% (N = 329). Technical success was achieved in 333 patients (96.0%). The clinical success rate at 30 days was 98.8% (N = 343). Three patients had limb occlusions at 30 day follow up (0.9%). One patient had a type Ib endoleak (0.3%). Seventy percent of vascular access approaches were percutaneous. The reintervention rate was 1.7% (N = 6) within 30 days. Indications for reinterventions were a false aneurysm at puncture site (N = 1), limb complications (N = 2), stentgraft-associated renal artery occlusions (N = 2), and an external iliac artery thrombosis (N = 1). CONCLUSIONS: Endovascular aneurysm repair using the Zenith Alpha Abdominal Endovascular Graft is effective in the short term. Long term results will be reported in the future.
引用
- Hatzl J, Batenburg MVB, Yeung KK, et al. Thirty-day Results from the ZEPHYR Registry: Outcomes of EVAR Using the Zenith Alpha™ Abdominal Endovascular Graft for the Treatment of AAA in 347 Patients. Ann Vasc Surg. 2021. PMID: 34474131. doi:10.1016/j.avsg.2021.06.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。